Gyre Therapeutics, Inc.

NASDAQ:GYRE

Biotechnology

Healthcare
$4.34 -0.15%

+$0.00 today

Market cap
$475.02M
Beta
4.92
P/E (TTM)
-88.3
EPS (TTM)
-$0.07
52W Low $5.44High $9.42

Volume 0.47M

Average 0.09M

GYRE Total Debt

Short-term and long-term borrowings combined.

Gyre Therapeutics, Inc.NASDAQ: GYRE

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 48.1% from a year ago

Total debt stood at $823K at the end of Q1 FY2026, down 48.1% from a year earlier and down 12.4% from the prior quarter. Over 3 fiscal years it compounded at +15.3% a year.

Context

  • Total debt amounted to 0.5% of total assets at the end of Q1 FY2026, down 0.7 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -48.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$823K-12.4% QoQ
Last fiscal yearDec 2025
$939K-41.2% YoY
Year agoMar 2025
$1.59M-48.1% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-48.1%——
1 year-41.2%——
3-year CAGR+15.3%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
939K USD
Year-over-year change
-41.2%
4-year CAGR
-20.8%

Total Debt vs competitors

How GYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -48.1% is the 3rd highest of 4, against a peer median of -14.9%.
  • Total debt amounts to 0.5% of total assets for GYRE, versus a peer median of 9.9%.
GYRE Competitors
Total Debt for GYRE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GALTGalectin Therapeutics Inc.Mar 2026$135.72M USD+25.7%+49.7%861.2%
PLRXPliant Therapeutics, Inc.Mar 2026$28.78M USD-52.2%+22.5%14.2%
SRZNSurrozen, Inc.Mar 2026$6.78M USD-14.9%+5.8%5.6%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€1.33M EUR——0.8%
GYREGyre Therapeutics, Inc.Mar 2026$823K USD-48.1%+15.3%0.5%
Peer median (excluding GYRE) —-14.9%+22.5%9.9%

Competitors are the stored peer set for GYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents44.35M25.18M33.51M11.81M37.07M
Short-term Investments2.5M0014.86M15.36M
Net Receivables1.82M15.61M16.84M29.15M36.95M
Inventory06.12M4.28M6.34M10.17M
Other Current Assets2.81M2.37M1.05M1.44M2.83M
Total Current Assets51.48M49.65M57.22M64.79M102.37M
Property, Plant & Equipment (Net)3.71M18.38M23.78M25.7M24.73M
Goodwill00000
Intangible Assets01.86M1.7M1.71M4.73M
Long-term Investments07.39M23.43M24.57M0
Tax Assets004.7M5.62M6.87M
Other Non-current Assets472K7.48M5.72M3.03M27.43M
Total Non-current Assets4.19M35.1M59.32M60.62M63.76M
Total Assets55.66M84.75M116.54M125.41M166.13M
Account Payables6.42M122K355K108K124K
Short-term Debt1.98M0000
Tax Payables005.05M2.83M2.94M
Deferred Revenue230K079K156K111K
Other Current Liabilities4.07M4.86M648K5.7M2.67M
Total Current Liabilities14.17M12.24M20.05M19.52M18.29M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00213K928K852K
Other Non-current Liabilities0173K82.13M5.68M4.41M
Total Non-current Liabilities408K294K82.54M7.49M5.56M
Total Liabilities14.57M12.54M102.59M27M23.85M
Common Stock31K64K77K86K91
Retained Earnings(402.69M)10.06M(85.54M)(73.45M)(68.43M)
Accumulated OCI40.23M(392K)1.45M501K2.32M
Other Stockholders Equity000090.91K
Minority Interest029.7M29.78M35.08M36.25M
Total Equity41.09M72.22M13.95M98.4M142.28M
Total Debt2.39M613K409K1.6M939K
Net Debt(41.96M)(24.56M)(33.1M)(10.22M)(36.13M)

Gyre Therapeutics, Inc.

NASDAQ:GYRE

Intrinsic Alpha fair value

Locked

Current Price

$4.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.